2024 Spain Hospital Tumor Marker Testing Market: Supplier Shares by Test and Strategies, Volume and Sales Segment Forecasts, Technology and Instrumentation Review, Emerging Opportunities

August 2024 | - | ID: 220E3CAA8839EN
Venture Planning Group

Abstracts

This new report from VPGMarketResearch contains 521 pages, 41 tables, and presents a comprehensive analysis of the Spanish hospital tumor marker testing market, including:

Contents

Introduction
Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology

1. BREST CANCER

2. LUNG CANCER

3. COLON AND RECTUM CANCER

4. PROSTATE CANCER

5. STOMACH CANCER

6. LEUKEMIA

7. LYMPHOMA

8. ORAL CANCER

9. SKIN CANCER

10. UTERINE CANCER

11. OVARIAN CANCER

12. BLADDER CANCER

B. Major Current And Emerging Cancer Diagnostic Tests

1. INTRODUCTION

2. TUMOR MARKER CLASSIFICATION

3. ACTH

4. ALPHA-FETOPROTEIN (AFP)

5. BETA-2 MICROGLOBULIN

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. CALCITONIN

10. CARCINOEMBRIONIC ANTIGEN (CEA)

11. ESTROGEN AND PROGESTERONE RECEPTORS

12. FERRITIN

13. GASTRIN

14. HUMAN CHORIONIC GONADOTROPIN (HCG)

15. INSULIN



16. NSE

17. OCCULT BLOOD

18. PAP SMEAR/HPV

19. PROSTATIC ACID PHOSPHATASE (PAP)

20. PROSTATE-SPECIFIC ANTIGEN (PSA)

21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)

22. T AND B LYMPHOCYTES

23. TDT

24. THYROGLOBULIN

25. TISSUE POLYPEPTIDE ANTIGEN (TPA)

26. BIOCHEMICAL TUMOR MARKERS

- ADA
- B-Protein
- PNP
- 5'-Nucleotidase

27. ONCOGENES

- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src


28. POLYPEPTIDE GROWTH FACTORS

- Basic Fibroblast Growt